ÌÇÐÄvlog

This population-based twin study estimates that the liability to autism spectrum disorder derives primarily from additive genetic and to a lesser extent nonshared environmental effects.

This national survey describes the limited effectiveness of an abuse-deterrent formulation of OxyContin and residual abuse among patients in drug treatment programs.

This 12-week, double-blind, randomized clinical trial of naltrexone vs placebo in individuals with alcohol dependence does not support the hypothesis that the Asp40 allele moderates the response to naltrexone treatment.

This case-control study examines whether mortality increases in elderly patients with dementia who receive antipsychotic medications.

This neuroimaging study demonstrates characteristic signatures of altered intracortical relationships in patients with deficit schizophrenia compared with those with nondeficit schizophrenia, patients with bipolar I disorder, and healthy individuals.

This population-based study finds that the pattern of functional abnormalities observed in youth with psychosis spectrum symptoms is similar to that previously found in schizophrenia and help-seeking risk samples.

In this large prospective cohort study, gastrointestinal symptoms were more common and persistent in children with autism spectrum disorder compared with children with typical development or developmental delay.

This randomized clinical trial reports that a dialectical behavior therapy (DBT) intervention that includes skills training is effective for reducing suicide and self-injury attempts in women with borderline personality disorder (BPD).

This nested case-control study reports a substantially increased risk for nonaffective psychotic disorder and bipolar disorder in individuals with an early diagnosis of autism spectrum disorder (ASD).

This cross-sectional study reports that global differences in gray matter volume may be due to alterations in the general mechanisms underlying normal brain development in attention-deficit/hyperactivity disorder.

This meta-analysis shows that various reporting biases are present for trials on the efficacy of US Food and Drug Administration–approved second-generation antidepressants for anxiety disorders.